Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**T cell receptor alpha joining 53 (TRAJ53)** is a genetic locus encoding a joining (J) segment of the T cell receptor alpha (TCRα) gene in humans[6][5]. This segment is a component of the DNA sequence that, through somatic recombination, helps generate the diversity of the antigen receptor of T lymphocytes as part of the adaptive immune response[3][7]. TRAJ53 itself does not encode a functional protein or receptor, but rather contributes, in combination with other V (variable) and C (constant) segments, to the final structure of the TCRα chain. It is not an individual therapeutic target, not a druggable protein, enzyme, receptor, or transporter, as it is only a genomic segment used in T cell development[6][5][3]. **Further detail:** - "TRAJ53" is one of many J (joining) gene segments within the complex TCRα locus, located on chromosome 14[6]. - The J gene segments like TRAJ53 provide sequence diversity for the CDR3 region, which is crucial for antigen recognition by T cells[3]. - Only full T cell receptors (e.g., the alpha-beta T cell receptor heterodimer) are considered "targets" in a therapeutic sense, not the individual joining segments[2][5]. **Summary:** TRAJ53 is a J gene segment of the T cell receptor alpha gene, not a distinct molecular target, receptor, or druggable entity, and so most fields regarding drugs, mechanisms, disease roles, and biomarkers are not applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 53 (TRAJ53).